Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00481975 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Rimonabant on Weight Loss and Frequency of Binge Episodes in Obese Patients
A Phase 3 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 3
- Development phase
- 289
- Enrollment target
NCT00481975 is a Phase 3 study that has completed, run by Sanofi. The registered enrollment target is 289 participants.
The verdict
NCT00481975, a Phase 3 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 289 participants
- Enrollment target
Study Summary
The primary objective is to assess the effect of rimonabant compared to placebo on weight loss over a period of 6 months when prescribed with a mild hypocaloric diet in obese patients with binge eating disorder. The secondary objectives are: * to assess the effect of rimonabant on the number of binge episodes per week, to assess the effect of rimonabant on eating behavior using the Binge Eating Scale (BES) and Three Factor Eating Questionnaire (TFEQ), * to evaluate the safety and tolerability of rimonabant over a period of 6 months.
Interventions
- DRUG rimonabant (SR141716)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 289 participants |
| Start Date | 2004-08 |
| Est. Completion | 2005-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00481975
The ClinicalTrials.gov registry entry for NCT00481975 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 289 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which rimonabant (SR141716) is the first listed.
NCT00481975 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00481975 about?
NCT00481975 is a clinical study titled "Efficacy and Safety of Rimonabant on Weight Loss and Frequency of Binge Episodes in Obese Patients". The primary objective is to assess the effect of rimonabant compared to placebo on weight loss over a period of 6 months when prescribed with a mild hypocaloric diet in obese patients with binge eating disorder. The secondary objectives are: * to assess the effect of rimonabant on the number of bi...
What is the current status of trial NCT00481975?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 289 participants. The study started on 2004-08. Estimated completion is 2005-08.
What interventions are being tested in trial NCT00481975?
The interventions under investigation include: rimonabant (SR141716) (DRUG).
Who is sponsoring clinical trial NCT00481975?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.